Search

Displaying results 4441 - 4450 of 10000 in total
  1. Drug

    Cyclo(his-pro)

    go.drugbank.com/drugs/DB02414
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  3. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  4. Drug

    Cositecan

    go.drugbank.com/drugs/DB05806
    Investigational

    Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.

  5. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. … After phase II trials it was cancelled due to lack of potency. [L2917]

  6. Drug

    Urea

    go.drugbank.com/drugs/DB03904
    ApprovedInvestigational

    A compound formed in the liver from ammonia produced by the deamination of amino acids. … It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.

  7. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  8. Drug

    ALKS 27

    go.drugbank.com/drugs/DB05752
    Experimental

    ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).

  9. Drug

    Ticalopride

    go.drugbank.com/drugs/DB06422
    Experimental

  10. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).